Treatment results of radiotherapy to both the prostate and metastatic sites in patients with bone metastatic prostate cancer

Journal of Radiation Research - Tập 62 Số 3 - Trang 511-516 - 2021
Koji Inaba1, Keisuke Tsuchida2,1, Tairo Kashihara1, Rei Umezawa1,3, Kana Takahashi1, Kae Okuma1, Naoya Murakami1, Yoshinori Ito1,4, Hiroshi Igaki1, Minako Sumi1,5, Yuko Nakayama1, Yasuo Shinoda6, Tomohiko Hara6, Yoshiyuki Matsui6, Motokiyo Komiyama6, Hiroyuki Fujimoto6, Jun Itami1
1Department of Radiation Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan
2Department of Radiation Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan
3Department of Radiation Oncology, Tohoku University Graduate School of Medicine, 1-1 Seiryou-machi, Aoba-ku, Sendai, Miyagi 980-8574, Japan
4Department of Radiation Oncology, Showa University School of Medicine, 1-5-8 Hatanodai, Shinagawa-ku, Tokyo 142-8666, Japan
5Department of Radiation Oncology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, 35-2 Sakae-cho, Itabashi-ku, Tokyo 173-0015, Japan
6Department of Urology, National Cancer Center Hospital, 5-1-1 Tsukiji Chuo-ku, Tokyo 104-0045, Japan

Tóm tắt

Abstract Although systemic therapy is the standard treatment for metastatic prostate cancer, a randomized controlled trial showed radiotherapy to the prostate improved overall survival of metastatic prostate cancer patients with the low metastatic burden. Additionally, a randomized phase II trial showed that metastasis-directed therapy for oligo-recurrent prostate cancer improved androgen-deprivation therapy (ADT)-free survival. Therefore, administering radiotherapy to both prostate and metastatic regions might result in better outcomes. Thus, we report the treatment results of radiotherapy to both prostate and metastatic regions. Our institutional database was searched for patients who received radiotherapy to the prostate and metastatic regions. We summarized patient characteristics and treatment efficacy and performed statistical analysis to find possible prognostic factors. A total of 35 patients were included in this study. The median age was 66 years, and the median initial prostate-specific antigen (PSA) level was 32 ng/ml. The Gleason score was 7 in 10 patients, 8 in 13 patients, and 9 in 12 patients. The median radiotherapy dose was 72 Gy to the prostate and 50 Gy to the metastatic bone region. The 8-year overall survival, cause-specific survival, progression-free survival, and freedom from biochemical failure rate were 81, 85, 53, and 57%. Among the 35 patients, 12 were disease-free even after ADT was discontinued. In selected patients with metastatic prostate cancer, ADT and radiotherapy to the prostate and metastatic sites were effective. Patients with good response to ADT may benefit from radiotherapy to both prostate and metastatic regions.

Từ khóa


Tài liệu tham khảo

Sweeney, 2015, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer, N Engl J Med, 373, 737, 10.1056/NEJMoa1503747

Fizazi, 2017, Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer, N Engl J Med, 377, 352, 10.1056/NEJMoa1704174

Kyriakopoulos, 2018, Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial, J Clin Oncol, 36, 1080, 10.1200/JCO.2017.75.3657

Clarke, Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial, Ann Oncol, 2019, 1992

Feyerabend, 2019, Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study, Target Oncol, 14, 681, 10.1007/s11523-019-00685-x

Sathianathen, Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis, Eur Urol, 2020, 365

Marchioni, 2020, New antiandrogen compounds compared to docetaxel for metastatic hormone sensitive prostate cancer: results from a network meta-analysis, J Urol, 10.1097/JU.0000000000000636

Halwani, 2020, Real-world practice patterns in veterans with metastatic castration-resistant prostate cancer, Urol Oncol, 38, 1.e1, 10.1016/j.urolonc.2019.09.027

Westerberg, 2020, Temporal changes in survival in men with de novo metastatic prostate cancer: nationwide population-based study, Acta Oncol, 59, 106, 10.1080/0284186X.2019.1662084

Lin, 2019, Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients, J Cancer, 10, 5608, 10.7150/jca.30731

Parker, 2018, Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial, Lancet, 392, 2353, 10.1016/S0140-6736(18)32486-3

Ost, 2018, Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial, J Clin Oncol, 36, 446, 10.1200/JCO.2017.75.4853

Tsumura, 2019, Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: a retrospective cohort study, Prostate, 79, 506, 10.1002/pros.23757

Sumi, 2000, The external radiotherapy with three-dimensional conformal boost after the neoadjuvant androgen suppression for patients with locally advanced prostatic carcinoma, Int J Radiat Oncol Biol Phys, 48, 519, 10.1016/S0360-3016(00)00614-3

Culp, 2014, Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study, Eur Urol, 65, 1058, 10.1016/j.eururo.2013.11.012

Engel, 2010, Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer, Eur Urol, 57, 754, 10.1016/j.eururo.2009.12.034

Knipper, 2020, Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H, World J Urol, 1459, 10.1007/s00345-019-02950-0

Thông tin
Thông tin xuất bản

Journal of Radiation Research

Tập 62 Số 3

511-516

Thông tin tác giả